Monday, 20 May 2019

Swiss CMO sets up manufacturing unit in China

03 September 2013 | News | By BioSpectrum Bureau

The new Siegfried plant will offer contract manufacturing for APIs, intermediates and finished oral drugs

The new Siegfried plant will offer contract manufacturing for APIs, intermediates and finished oral drugs

Singapore: Switzerland-based contract manufacturing organization (CMO), Siegfried Holdings, has started the construction of its new pharma manufacturing plant in Nantong, China.

The new plant, which would be the company's first facility in China, will have a capacity of 300 cubic meters. Siegfried will offer contract manufacturing for APIs, intermediates and finished oral drugs, along with other development services at its new plant.

Presently, Siegfried has plants in Switzerland, Malta and the US.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

 

Survey Box

Will stem cell therapy market witness highest growth in Asia by 2020?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls